The Pulmonary Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Hypertension. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Hypertension and features dormant and discontinued products.

GlobalData tracks 163 drugs in development for Pulmonary Hypertension by 135 companies/universities/institutes. The top development phase for Pulmonary Hypertension is preclinical with 76 drugs in that stage. The Pulmonary Hypertension pipeline has 147 drugs in development by companies and 16 by universities/ institutes. Some of the companies in the Pulmonary Hypertension pipeline products market are: United Therapeutics, Bayer and Chiesi Farmaceutici.

The key targets in the Pulmonary Hypertension pipeline products market include Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR), cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35), and Platelet Derived Growth Factor Receptor (PDGFR or EC 2.7.10.1).

The key mechanisms of action in the Pulmonary Hypertension pipeline product include Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) Agonist with 15 drugs in Pre-Registration. The Pulmonary Hypertension pipeline products include 14 routes of administration with the top ROA being Oral and 17 key molecule types in the Pulmonary Hypertension pipeline products market including Small Molecule, and Monoclonal Antibody.

Pulmonary Hypertension overview

Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen therapy, lifestyle adjustments, and, in severe cases, surgery or lung transplantation. Early diagnosis and treatment are vital to alleviate symptoms, improve quality of life, and enhance the prognosis for individuals with PH.

For a complete picture of Pulmonary Hypertension’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.